NEW YORK (GenomeWeb News) – Roche today reported that its sales for its molecular diagnostics products fell 3 percent for the first quarter as revenues for its Diagnostics Division overall grew 1 percent.

The Swiss diagnostics, pharmaceuticals, and research products firm reported total group sales of CHF 11.59 billion ($12.45 billion), up 5 percent year over year, and driven by its pharmaceutical products sales, which rose 6 percent to CHF 9.17 billion from CHF 8.62 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.